Breast Cancer

Aromatase inhibitors in breast cancer assessed by ASCO Committee

Published in Women's Health Weekly, June 20th, 2002

Data from recent studies on the use of aromatase inhibitors in the treatment of postmenopausal women with breast cancer has generated significant interest from the medical oncology community and has prompted organizations to evaluate current treatment regimens.

Following data presented in December at a major breast cancer conference, the American Society of Clinical Oncology (ASCO) convened a blue ribbon panel to review the use of aromatase inhibitors.

Specific to the adjuvant breast cancer setting, the Committee reviewed the ATAC (Arimidex [anastrozole], tamoxifen alone or in combination) data and declined to recommend the use of aromatase...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-06-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry